Is intravitreal bevacizumab treatment effective in diffuse diabetic macular edema?

Graefe's Archive for Clinical and Experimental Ophthalmology

Volumn 247, Issue 11, 2009, Pages 1575-1577

  Biester, Sabine ^a   Ziemssen, Focke ^a   Ulrich Bartz Schmidt, Karl ^a   Gelisken, Faik ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB;

BEST CORRECTED VISUAL ACUITY; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETIC MACULAR EDEMA; DRUG EFFICACY; EYE EXAMINATION; FLUORESCENCE ANGIOGRAPHY; FOLLOW UP; HUMAN; LETTER; OPTICAL COHERENCE TOMOGRAPHY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RETINA THICKNESS;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; DIABETIC RETINOPATHY; FLUORESCEIN ANGIOGRAPHY; HUMANS; INJECTIONS; MACULAR EDEMA; RETROSPECTIVE STUDIES; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; VITREOUS BODY;

EID: 70349878483     PISSN: 0721832X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00417-009-1132-4     Document Type: Letter

References (9)

1. Klein R, Klein BE, Moss SE (1984) Visual impairment in diabetes. Ophthalmology 91:1-9
2. Early Treatment Diabetic Retinopathy Study Research Group (1985) Photocoagulation for diabetic macular edema. Early treatment diabetic retinopathy study report number 1. Arch Ophthalmol 103:1796-1806
3. Diabetic Retinopathy Clinical Research Network (DRCR.net), Beck RW, Edwards AR, Aiello LP, Bressler NM, Ferris F, Glassmann AR, Hartnett E, Ip MS, Kim JE, Kollmann C (2009) Three-year follow-up of a randomized trial comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema. Arch Ophthalmol 127:245-251. doi: 10.1001/archophthalmol.2008.610
4. Lee CM, Olk RJ (1983) Modified grid laser photocoagulation for diffuse diabetic macular edema: Long-term results. Ophthalmology 90:1301-1317
5. Funatsu H, Yamashita H, Sakata K, Noma H, Mimura T, Suzuki M, Eguchi S, Horis S (2005) Vitreous levels of vascular endothelial growth factor and intercellular adhesion molecule 1 are related to diabetic macular edema. Ophthalmology 112:806-816. doi: 10.1016/j.ophtha.2004.11.045
6. Haritoglou C, Kook D, Neubauer A, Wolf A, Priglinger S, Strauss R, Gandorfer A, Ulbig M, Kampik A (2006) Intravitreal bevacizumab (Avastin) therapy for persistant diffuse diabetic macular edema. Retina 26:999-1005. doi: 10.1097/01.iae.0000247165.38655.bf
7. Arevalo JF, Sanchez JG, Fromow-Guerra J, Wu L, Berrocal MH, Farah ME, Cardillo J, Rodriguez FJ, Pan-American Collaborative Retina Study Group (PACORES) (2009) Comparison of two doses of primary intravitreal bevacizumab (Avastin) for diffuse diabetic macular edema: Results from the Pan-American Collaborative Retina Study Group (PACORES) at 12-month follow-up. Graefes Arch Clin Exp Ophthalmol. Epub ahead of print. doi: 10.1007/s00417-008-1034-x
8. Olk RJ (1986) Modified grid argon (blue-green) laser photocoagulation for diffuse diabetic macular edema. Ophthalmology 93:938-950
9. Browning DJ, Altaweel MM, Bressler NM, Bressler SB, Scott IU, Diabetic Retinopathy Clinical Research Network (2008). Diabetic macular edema: What is focal and what is diffuse? Am J Ophthalmol 146(5):649-55,655.e1-6